Neogen Revenue Growth Rates (NEOG), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Neogen Corporation  (NASDAQ: NEOG)
 

NEOG's Revenue Growth by Quarter and Year

Neogen's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NEOG Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter May 225.54
3rd Quarter February 211.00
2nd Quarter November 224.68
1st Quarter August 208.97
FY 870.19

NEOGs Annual Revenue
Neogen's Revenue in the fiscal year 2026 $ 870.60 millions
Neogen's Revenue in the fiscal year 2025 $ 894.38 millions
Neogen's Revenue in the fiscal year 2024 $ 923.90 millions
Neogen's Revenue in the fiscal year 2023 $ 821.96 millions
Neogen's Revenue in the fiscal year 2022 $ 527.16 millions




NEOG Revenue fourth quarter 2025 Y/Y Growth Comment
Neogen Corporation reported decrease in Revenue in the fourth quarter 2025 by -0.58% to $ 225.54 millions, from the same quarter in 2024.
The decrease in the fourth quarter 2025 Neogen Corporation's Revenue compares unfavorably to the Company's average Revenue increase of 12.67%.

Looking into fourth quarter 2025 results within In Vitro & In Vivo Diagnostic Substances industry 7 other companies have achieved higher Revenue growth. While Neogen Corporation' s Revenue decline of -0.58% ranks overall at the positon no. 2731 in the fourth quarter 2025.


NEOG Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter May -0.58 % -4.19 % -1.88 % 72.26 %
3rd Quarter February -4.21 % -3.34 % 4.41 % 70.2 %
2nd Quarter November -2.45 % 0.3 % -0.17 % 76.24 %
1st Quarter August -3.67 % -5.17 % 72.84 % 3.15 %
FY   -2.71 % -3.11 % 12.3 % -

Financial Statements
Neogen's fourth quarter 2025 Revenue $ 225.54 millions NEOG's Income Statement
Neogen's fourth quarter 2024 Revenue $ 226.86 millions Quarterly NEOG's Income Statement


NEOG Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter May 6.89 % 2.99 % 3.91 % 10.57 %
3rd Quarter February -6.09 % -4.37 % -0.76 % -5.12 %
2nd Quarter November 7.52 % 6.18 % 0.38 % 73.8 %
1st Quarter August -7.89 % -8.39 % -5.2 % -5.53 %
FY (Year on Year)   -2.71 % -3.11 % 12.3 % -


Back to NEOG Growth rate Comparisons >> Back to NEOG Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #8
Healthcare Sector #388
Overall #2731

Revenue Y/Y Growth Statistics
High Average Low
72.88 % 12.67 % -3.63 %
(Aug 31 2023)   (Feb 28 2026)
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #8
Healthcare Sector #388
Overall #2731
Revenue Y/Y Growth Statistics
High Average Low
72.88 % 12.67 % -3.63 %
(Aug 31 2023)   (Feb 28 2026)

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Neogen's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
73.81 % 3.15 % -8.84 %
(Nov 30 2022)  


NEOG's IV. Quarter Q/Q Revenue Comment
Neogen Corporation achieved in the IV. Quarter 2025 above company average sequential Revenue increase of 6.89%, to $ 225.54 millions, from $211.00 millions in the third quarter.
NEOG is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within In Vitro & In Vivo Diagnostic Substances industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Neogen's Revenue growth quarter on quarter, overall rank is 1009.


Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #3
Healthcare Sector #150
Overall #1009
Revenue Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #3
Healthcare Sector #150
Overall #1009
Revenue Q/Q Growth Statistics
High Average Low
73.81 % 3.15 % -8.84 %
(Nov 30 2022)  


NEOG's IV. Quarter Q/Q Revenue Comment
Neogen Corporation achieved in the IV. Quarter 2025 above company average sequential Revenue increase of 6.89%, to $ 225.54 millions, from $211.00 millions in the third quarter.
NEOG is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within In Vitro & In Vivo Diagnostic Substances industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Neogen's Revenue growth quarter on quarter, overall rank is 1009.


Neogen's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(May 31 2026)		 12 Months Ending
(Feb 28 2026)		 12 Months Ending
(Nov 30 2025)		 12 Months Ending
(Aug 31 2025)		 12 Months Ending
(May 31 2025)
Cumulative Revenue 12 Months Ending $ 870.19 $ 871.51 $ 880.77 $ 886.42 $ 894.38
Y / Y Revenue Growth (TTM) -2.7 % -3.63 % -3.42 % -2.72 % -3.11 %
Year on Year Revenue Growth Overall Ranking # 2892 # 45 # 37 # 11 # 16
Seqeuential Revenue Change (TTM) -0.15 % -1.05 % -0.64 % -0.89 % -1.1 %
Seq. Revenue Growth (TTM) Overall Ranking # 2731 # 46 # 329 # 49 # 290


Cumulative Revenue growth Comment
Neogen showed decline, but improvement compare to trailing twelve month Revenue decrease in Feb 28 2026. If the fiscal year would end in May 31 2026, Neogen's annual Revenue decline would be -2.7% year on year to $870 millions.

In the Healthcare sector 405 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 45 to 2892.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 8
Healthcare Sector # 406
Overall # 2892

Revenue TTM Y/Y Growth Statistics
High Average Low
72.88 %
 12.67 %
-3.63 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 388
S&P 500 # 2731
Cumulative Revenue growth Comment
Neogen showed decline, but improvement compare to trailing twelve month Revenue decrease in Feb 28 2026. If the fiscal year would end in May 31 2026, Neogen's annual Revenue decline would be -2.7% year on year to $870 millions.

In the Healthcare sector 405 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 45 to 2892.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 8
Healthcare Sector # 406
Overall # 2892

Revenue TTM Y/Y Growth Statistics
High Average Low
72.88 %
12.67 %
-3.63 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 388
S&P 500 # 2731




Other Revenue Growth
In Vitro & In Vivo Diagnostic Substances Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NEOG's Revenue Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decline for the quarter ending May 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending May 31 2026
Neogen Corporation-0.58%$ -0.581 millions
Cryo cell International Inc -1.93%$ -1.926 millions
Nurix Therapeutics Inc -79.47%$ -79.474 millions


About Neogen Revenue Growth Rates (NEOG), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Neogen Corp (CIK 711377).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-326092
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Neogen Corp’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.